A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Inclusion Criteria:

1. Confirmed diagnosis of symptomatic multiple myeloma and measurable secretory disease
2. For carfilzomib-lenalidomide-dexamethasone (KRd) regimen: newly diagnosed myeloma. For carfilzomib-dexamethasone (CFZ-dex) regimen: relapsed or refractory disease
3. Eastern Cooperative Oncology Group performance status score of 0, 1, or 2
4. Pretreatment clinical laboratory values must meet protocol-defined parameters during the screening phase

Exclusion Criteria:

1. Previously received daratumumab or other anti-CD38 therapies
2. Diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, Waldenström's disease, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions
3. Peripheral neuropathy or neuropathic pain Grade 2 or higher
4. Prior or concurrent invasive malignancy (other than multiple myeloma) within 5 years of study start
5. Exhibiting clinical signs of meningeal involvement of multiple myeloma
6. Known chronic obstructive pulmonary disease, persistent asthma, or a history of asthma within 2 years
7. Seropositive for human immunodeficiency virus, hepatitis B, or hepatitis C
8. Any concurrent medical or psychiatric condition or disease that is likely to interfere with the study procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this study
9. Clinically significant cardiac disease
10. Plasma cell leukemia or POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) syndrome